Initiator Pharma (INIT) Stock Overview
A clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
INIT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Initiator Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.14 |
| 52 Week High | SEK 8.25 |
| 52 Week Low | SEK 2.56 |
| Beta | 0.14 |
| 1 Month Change | 3.63% |
| 3 Month Change | -16.93% |
| 1 Year Change | -56.08% |
| 3 Year Change | -47.05% |
| 5 Year Change | -37.20% |
| Change since IPO | -45.86% |
Recent News & Updates
Recent updates
We Think Initiator Pharma (STO:INIT) Can Afford To Drive Business Growth
Mar 04
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
May 31Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?
Feb 27Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
May 20Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
Jan 06We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
Oct 26We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate
Jun 12Shareholder Returns
| INIT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 7.9% | -0.7% | 0.4% |
| 1Y | -56.1% | -0.9% | 2.2% |
Return vs Industry: INIT underperformed the Swedish Biotechs industry which returned -0.9% over the past year.
Return vs Market: INIT underperformed the Swedish Market which returned 2.2% over the past year.
Price Volatility
| INIT volatility | |
|---|---|
| INIT Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: INIT has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: INIT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 2 | Claus Olesen | www.initiatorpharma.com |
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The company also develops IP2016, which is in preclinical development for the treatment of depression and pain; and Pudafensine and IP2018, which is in preclinical development to treat female sexual dysfunction.
Initiator Pharma A/S Fundamentals Summary
| INIT fundamental statistics | |
|---|---|
| Market cap | SEK 214.94m |
| Earnings (TTM) | -SEK 17.03m |
| Revenue (TTM) | n/a |
Is INIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INIT income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 10.63m |
| Gross Profit | -DKK 10.63m |
| Other Expenses | DKK 990.00k |
| Earnings | -DKK 11.62m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 20, 2026
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.6% |
How did INIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/05 01:46 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Initiator Pharma A/S is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Palin | DNB Carnegie Commissioned Research |
| Kevin Sule | Redeye |